Arbutus Biopharma Corp. is a biopharmaceutical company, engages in discovering, developing and commercializing a cure for patients suffering from chronic Hepatitis B virus infection. The company was founded on October 6, 2005 and is headquartered in Burnaby, Canada.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone604-419-3200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$5.90 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/2/2019 (Estimated)
OptionableOptionable
Arbutus Biopharma (NASDAQ:ABUS) Frequently Asked Questions
What is Arbutus Biopharma's stock symbol?
Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."
How were Arbutus Biopharma's earnings last quarter?
Arbutus Biopharma Corp (NASDAQ:ABUS) announced its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.39) by $0.02. The biopharmaceutical company had revenue of $1.60 million for the quarter, compared to analysts' expectations of $0.77 million. Arbutus Biopharma had a negative net margin of 986.23% and a negative return on equity of 74.52%. View Arbutus Biopharma's Earnings History.
When is Arbutus Biopharma's next earnings date?
What price target have analysts set for ABUS?
5 Wall Street analysts have issued 12-month price targets for Arbutus Biopharma's shares. Their forecasts range from $5.00 to $9.00. On average, they anticipate Arbutus Biopharma's stock price to reach $6.8333 in the next twelve months. This suggests a possible upside of 128.5% from the stock's current price. View Analyst Price Targets for Arbutus Biopharma.
What is the consensus analysts' recommendation for Arbutus Biopharma?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Arbutus Biopharma.
Has Arbutus Biopharma been receiving favorable news coverage?
News articles about ABUS stock have trended positive this week, InfoTrie reports. The research firm identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Arbutus Biopharma earned a news sentiment score of 2.7 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term.
Who are some of Arbutus Biopharma's key competitors?
Some companies that are related to Arbutus Biopharma include Evolus (EOLS), Viking Therapeutics (VKTX), Vectura Group (VEGPF), DiaMedica Therapeutics (DMCAF), Lexicon Pharmaceuticals (LXRX), Vital Therapies (VTL), Odonate Therapeutics (ODT), Obseva (OBSV), Dermira (DERM), Kura Oncology (KURA), Revance Therapeutics (RVNC), Forty Seven (FTSV), Aurinia Pharmaceuticals (AUPH), ZEALAND PHARMA/S (ZEAL) and OvaScience (OVAS).
What other stocks do shareholders of Arbutus Biopharma own?
Who are Arbutus Biopharma's key executives?
Arbutus Biopharma's management team includes the folowing people:
- Mark J. Murray, President, Chief Executive Officer & Director
- David C. Hastings, Chief Financial Officer
- Michael J. Sofia, Chief Scientific Officer
- Elizabeth Howard, Executive Vice President & General Counsel
- James Heyes, Vice President-Drug Delivery
How do I buy shares of Arbutus Biopharma?
Shares of ABUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arbutus Biopharma's stock price today?
One share of ABUS stock can currently be purchased for approximately $2.99.
How big of a company is Arbutus Biopharma?
Arbutus Biopharma has a market capitalization of $167.80 million and generates $5.90 million in revenue each year. The biopharmaceutical company earns $-57,060,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis.
What is Arbutus Biopharma's official website?
How can I contact Arbutus Biopharma?
Arbutus Biopharma's mailing address is 100-8900 GLENLYON PARKWAY, BURNABY A1, V5J 5J8. The biopharmaceutical company can be reached via phone at 604-419-3200 or via email at [email protected]
MarketBeat Community Rating for Arbutus Biopharma (NASDAQ ABUS)
MarketBeat's community ratings are surveys of what our community members think about Arbutus Biopharma and other stocks. Vote "Outperform" if you believe ABUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ABUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
